* CytomX Therapeutics Inc CTMX.OQ reported a quarterly
adjusted
loss of 8 cents per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of -2 cents. The mean expectation of seven analysts for the
quarter was for a loss of 14 cents per share. Wall Street
expected results to range from -25 cents to -1 cents per share.
* Revenue rose 1.6% to $25.12 million from a year ago;
analysts
expected $19.99 million.
* CytomX Therapeutics Inc's reported EPS for the quarter was
a
loss of 8 cents.
* The company reported a quarterly loss of $6.53 million.
* CytomX Therapeutics Inc shares had fallen by 4.9% this
quarter and lost 25.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 4.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $3.59
This summary was machine generated from LSEG data August 8 at
11:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.14 -0.08 Beat
Mar. 31 2024 -0.08 0.17 Beat
Dec. 31 2023 -0.03 0.01 Beat
Sep. 30 2023 -0.19 0.04 Beat